+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Hyperimmune Globulins Market - Global Forecast 2026-2032- Product Image
Human Hyperimmune Globulins Market - Global Forecast 2026-2032- Product Image
Sale

Human Hyperimmune Globulins Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6125787
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Hyperimmune Globulins Market is projected to reach USD 1.04 Billion in 2026. It is expected to continue growing at a CAGR of 9.52%, reaching USD 1.81 Billion by 2032.

Human Hyperimmune Globulins: Executive Overview

Human hyperimmune globulins are plasma-derived immunoglobulin products containing elevated levels of antibodies directed against specific pathogens or antigens. They are used in targeted prevention or post-exposure settings where immediate, passive immune protection is clinically valuable. The market is shaped by infectious-disease epidemiology, plasma collection capacity, donor eligibility, manufacturing controls, clinical guidance, and public-health procurement.

Supply Security and Clinical Prioritization Are Reshaping the Landscape

The landscape is undergoing a shift from product availability alone toward resilient, quality-assured supply. Manufacturers and health systems must manage donor recruitment, plasma testing, fractionation capacity, pathogen-safety controls, cold-chain requirements, and allocation during outbreaks. Regulatory expectations increasingly emphasize traceability, validated viral-reduction processes, consistent potency, and evidence supporting use in defined patient populations. Clinical adoption is also becoming more selective as alternatives, vaccination programs, and evolving treatment guidelines influence demand for passive immunization.

Artificial Intelligence Strengthens Quality, Planning, and Evidence Generation

Artificial intelligence can support the sector by improving plasma-collection planning, identifying operational bottlenecks, detecting anomalies in manufacturing and laboratory data, and assisting demand-signal analysis during infectious-disease events. Machine-learning tools may also help prioritize quality investigations, optimize inventory rotation, and accelerate review of scientific literature and post-market safety reports. These applications require validated data pipelines, human oversight, cybersecurity controls, and regulatory documentation; AI should augment rather than replace expert decisions on donor safety, product release, clinical eligibility, or pharmacovigilance.

Regional Insights: Regulation, Plasma Infrastructure, and Outbreak Readiness

North America combines advanced fractionation infrastructure with stringent regulatory oversight and established hospital procurement systems, while Latin America continues to face uneven donor access, import dependence, and differences in regulatory maturity. Europe emphasizes harmonized quality requirements, traceability, and coordinated public-health preparedness, although national reimbursement and procurement practices remain important. The Middle East is developing specialized healthcare capacity and may rely on strategic imports, whereas Africa’s access is constrained by plasma-collection infrastructure, financing, logistics, and laboratory capacity. Asia-Pacific presents highly diverse conditions: Australia, Japan, and South Korea have sophisticated regulatory and clinical systems, while several other markets are expanding domestic plasma and biologics capabilities alongside broader immunization and infectious-disease programs.

Group Insights: Cooperation Can Improve Resilience and Access

ASEAN cooperation is relevant to regulatory alignment, cross-border supply continuity, and infectious-disease preparedness across varied health systems. BRICS members span major plasma, manufacturing, research, and public-health capabilities, but differ substantially in regulation, reimbursement, and domestic production priorities. The European Union benefits from coordinated scientific and regulatory mechanisms while retaining national differences in procurement and clinical implementation. G7 members generally combine strong pharmacovigilance and biologics oversight with mature healthcare infrastructure. GCC countries can use centralized procurement, investment in specialist care, and regional stock-management approaches to strengthen access. NATO members may benefit from shared preparedness planning, logistics coordination, and continuity strategies for critical biological products, while recognizing that civilian regulatory and clinical systems remain central.

Country Insights: Diverse National Priorities Shape Adoption

Australia emphasizes regulatory quality, hospital preparedness, and geographically reliable distribution. Brazil combines substantial public-health needs with a complex regulatory and procurement environment, while Canada focuses on supply continuity across a large geography. China is expanding biopharmaceutical capability and regulatory sophistication; India combines a large clinical base with growing manufacturing and public-health capacity. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom operate within mature regulatory and clinical ecosystems, with national differences in reimbursement, procurement, and infectious-disease policy. The United States has extensive plasma and specialty-biologics infrastructure but faces ongoing requirements for donor recruitment, quality assurance, and equitable distribution. Mexico continues to balance access, import requirements, and healthcare-system capacity. Russia’s operating environment reflects national regulatory, supply-chain, and healthcare priorities that can affect availability and international coordination.

Priorities for Industry Leaders: Build Trust, Resilience, and Clinical Relevance

Industry leaders should diversify qualified plasma sources, strengthen donor-retention programs, and maintain redundant capabilities for testing, fractionation, fill-finish, storage, and distribution. They should align product development with clearly defined clinical use cases, generate robust evidence for safety and effectiveness, and engage regulators and public-health authorities early. Scenario planning should cover outbreaks, transport disruption, changing guidelines, and regional shortages. Digital quality systems, validated analytics, transparent traceability, and disciplined pharmacovigilance can improve reliability. Partnerships with hospitals, blood services, governments, and research institutions should focus on preparedness, responsible allocation, and access rather than volume expansion alone.

Research Methodology: Evidence-Based Market Assessment

This executive summary uses the defined human hyperimmune globulins market scope and organizes analysis around product purpose, clinical use, regulation, supply infrastructure, public-health preparedness, and geographic operating conditions. Insights should be validated through primary interviews with clinicians, regulators, plasma-collection organizations, manufacturers, distributors, and procurement bodies, complemented by peer-reviewed literature, official guidance, pharmacovigilance disclosures, clinical-trial records, and public-health data. Regional, group, and country comparisons should account for differences in epidemiology, healthcare financing, donor systems, regulatory pathways, reimbursement, logistics, and local manufacturing. No market estimates, market shares, forecasts, or company-level comparisons are used.

Conclusion: Preparedness and Evidence Will Define Sustainable Progress

Human hyperimmune globulins remain strategically important where rapid, targeted passive protection is required and vaccination or other interventions are insufficient, unsuitable, or unavailable. Sustainable progress depends on reliable plasma access, rigorous manufacturing and safety controls, clinically appropriate use, and coordinated public-health planning. Organizations that combine scientific discipline with supply-chain resilience, responsible data use, and regionally informed access strategies will be better positioned to support patients and health systems across diverse markets.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Human Hyperimmune Globulins Market, by Product Type
7.1. Introduction
7.2. Cytomegalovirus Immunoglobulin
7.3. Hepatitis B Immunoglobulin
7.4. Rabies Immunoglobulin
7.5. Tetanus Immunoglobulin
7.6. Varicella Zoster Immunoglobulin
8. Human Hyperimmune Globulins Market, by Route of Administration
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Subcutaneous
9. Human Hyperimmune Globulins Market, by Application
9.1. Introduction
9.2. Post-Exposure Prophylaxis
9.2.1. Animal Bite
9.2.2. Blood Transfusion Exposure
9.2.3. Needlestick Injury
9.3. Therapeutic Use
10. Human Hyperimmune Globulins Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Clinics
10.4. Hospitals
11. Human Hyperimmune Globulins Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Human Hyperimmune Globulins Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Human Hyperimmune Globulins Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. ADMA Biologics, Inc.
15.2. Bayer AG
15.3. Bio Products Laboratory Ltd.
15.4. Biotest AG
15.5. China Biologic Products Holdings, Inc.
15.6. CSL Behring LLC
15.7. Emergent BioSolutions Inc.
15.8. Fresenius Kabi AG
15.9. GC Biopharma Co., Ltd.
15.10. Grifols, S.A.
15.11. Hualan Biological Engineering, Inc.
15.12. Kamada Ltd.
15.13. Kedrion S.p.A.
15.14. Novartis AG
15.15. Octapharma AG
15.16. Pfizer Inc.
15.17. Sanofi S.A.
15.18. Shanghai RAAS Blood Products Co., Ltd.
15.19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
15.20. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Human Hyperimmune Globulins Market, Years Considered for the Study
FIGURE 2. Global Human Hyperimmune Globulins Market, Research Design
FIGURE 3. Global Human Hyperimmune Globulins Market, Research Framework
FIGURE 4. Global Human Hyperimmune Globulins Market, Data Triangulation
FIGURE 5. Global Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Human Hyperimmune Globulins Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Human Hyperimmune Globulins Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Human Hyperimmune Globulins Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Human Hyperimmune Globulins Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Human Hyperimmune Globulins Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Human Hyperimmune Globulins Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Human Hyperimmune Globulins Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Human Hyperimmune Globulins Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Human Hyperimmune Globulins Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Human Hyperimmune Globulins Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Human Hyperimmune Globulins Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Human Hyperimmune Globulins Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Human Hyperimmune Globulins Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Human Hyperimmune Globulins Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Human Hyperimmune Globulins Market Segmentation & Coverage
TABLE 2. Global Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 3. Global Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Cytomegalovirus Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cytomegalovirus Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cytomegalovirus Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hepatitis B Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hepatitis B Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hepatitis B Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Rabies Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Rabies Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Rabies Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Tetanus Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Tetanus Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Tetanus Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Varicella Zoster Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Varicella Zoster Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Varicella Zoster Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 20. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 30. Global Post-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Post-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Post-Exposure Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Animal Bite Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Animal Bite Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Animal Bite Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Blood Transfusion Exposure Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Blood Transfusion Exposure Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Blood Transfusion Exposure Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Needlestick Injury Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Needlestick Injury Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Needlestick Injury Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Therapeutic Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Therapeutic Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Therapeutic Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 46. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 62. North America Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. North America Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 64. North America Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 65. North America Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 66. North America Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 67. North America Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Latin America Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 70. Latin America Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 71. Latin America Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 72. Latin America Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 73. Latin America Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Europe Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Europe Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. Europe Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 77. Europe Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 78. Europe Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 79. Europe Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Middle East Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Middle East Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 82. Middle East Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 83. Middle East Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 84. Middle East Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 85. Middle East Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Africa Human Hyperimmune Globulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Africa Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 88. Africa Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 89. Africa Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 90. Africa Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 91. Africa Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Global Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. ASEAN Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. ASEAN Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. ASEAN Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 96. ASEAN Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 97. ASEAN Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 98. ASEAN Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. GCC Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. GCC Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. GCC Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 102. GCC Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 103. GCC Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 104. GCC Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. European Union Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. European Union Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. European Union Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 108. European Union Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 109. European Union Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 110. European Union Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. BRICS Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. BRICS Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. BRICS Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 114. BRICS Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 115. BRICS Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 116. BRICS Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. G7 Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. G7 Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 119. G7 Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 120. G7 Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 121. G7 Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 122. G7 Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. NATO Human Hyperimmune Globulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. NATO Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 125. NATO Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 126. NATO Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. NATO Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 128. NATO Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Global Human Hyperimmune Globulins Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. United States Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 131. United States Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. United States Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 133. United States Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 134. United States Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 135. United States Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Canada Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 137. Canada Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. Canada Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 139. Canada Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 140. Canada Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 141. Canada Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Mexico Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 143. Mexico Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. Mexico Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 145. Mexico Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. Mexico Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 147. Mexico Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Brazil Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 149. Brazil Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 150. Brazil Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 151. Brazil Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 152. Brazil Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 153. Brazil Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. United Kingdom Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 155. United Kingdom Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. United Kingdom Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 157. United Kingdom Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 158. United Kingdom Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 159. United Kingdom Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Germany Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 161. Germany Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 162. Germany Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 163. Germany Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 164. Germany Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 165. Germany Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. France Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 167. France Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. France Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 169. France Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 170. France Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 171. France Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Russia Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 173. Russia Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 174. Russia Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 175. Russia Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 176. Russia Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 177. Russia Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Italy Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 179. Italy Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. Italy Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 181. Italy Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 182. Italy Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 183. Italy Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Spain Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 185. Spain Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 186. Spain Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 187. Spain Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 188. Spain Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 189. Spain Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. China Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 191. China Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 192. China Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 193. China Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. China Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 195. China Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. India Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 197. India Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. India Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 199. India Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 200. India Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 201. India Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Japan Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 203. Japan Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 204. Japan Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 205. Japan Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 206. Japan Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 207. Japan Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Australia Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 209. Australia Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 210. Australia Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 211. Australia Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 212. Australia Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 213. Australia Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. South Korea Human Hyperimmune Globulins Market Size, 2017-2032 (USD Million)
TABLE 215. South Korea Human Hyperimmune Globulins Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 216. South Korea Human Hyperimmune Globulins Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 217. South Korea Human Hyperimmune Globulins Market Size, by Application, 2017-2032 (USD Million)
TABLE 218. South Korea Human Hyperimmune Globulins Market Size, by Post-Exposure Prophylaxis, 2017-2032 (USD Million)
TABLE 219. South Korea Human Hyperimmune Globulins Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Global Human Hyperimmune Globulins Market Share, by Key Player, 2025
TABLE 221. Global Human Hyperimmune Globulins Market, Key Experts

Companies Mentioned

  • ADMA Biologics, Inc.
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring LLC
  • Emergent BioSolutions Inc.
  • Fresenius Kabi AG
  • GC Biopharma Co., Ltd.
  • Grifols, S.A.
  • Hualan Biological Engineering, Inc.
  • Kamada Ltd.
  • Kedrion S.p.A.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Plasma Protein Therapeutics Market - Global Forecast 2026-2032 - Product Image

Plasma Protein Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Plasma Protein Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Plasma Protein Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 115 Pages
  • Global
From
Plasma Protein Products Market - Global Forecast 2026-2032 - Product Image

Plasma Protein Products Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Plasma Protein Therapeutics Market Report 2026 - Product Image

Plasma Protein Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Polyclonal Antibodies Market Report 2026 - Product Image

Polyclonal Antibodies Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.